Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Recent & Breaking News (NDAQ:MRNA)

Biotechs Offer a Glimmer of Hope Amid the Deadly COVID-19 Outbreak

Livemoney March 20, 2020

The Top Ways to Ward Off Infection, according to Health Experts

Livemoney March 19, 2020

Moderna Announces First Participant Dosed in NIH-led Phase 1 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

Business Wire March 16, 2020

Moderna Completes Enrollment of Cytomegalovirus (CMV) Vaccine (mRNA-1647) Phase 2 Study

Business Wire March 3, 2020

Moderna Announces Updated Plans for its March 4 Manufacturing & Digital Day Event

Business Wire March 2, 2020

Moderna to Host Manufacturing & Digital Day on March 4, 2020

Business Wire February 26, 2020

Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities

Business Wire February 26, 2020

Moderna Ships mRNA Vaccine Against Novel Coronavirus (mRNA-1273) for Phase 1 Study

Business Wire February 24, 2020

Moderna to Present at Upcoming Investor Conferences

Business Wire February 24, 2020

Moderna to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26th, 2020

Business Wire February 12, 2020

Moderna Announces Pricing of Public Offering of Shares of Common Stock

Business Wire February 11, 2020

Moderna Announces Progress in Prophylactic Vaccines Modality with CMV Vaccine Phase 2 Study Data Now Expected in Third Quarter 2020 and Expands Investment in This Core Modality with Three New Development Candidates

Business Wire February 10, 2020

Moderna Announces First Patient Enrolled in Phase 1/2 Study of mRNA-3704 for Methylmalonic Acidemia

Business Wire February 10, 2020

Moderna Announces Proposed Public Offering of Shares of Common Stock

Business Wire February 10, 2020

Sandra Horning, M.D. To Join Moderna's Board of Directors

Business Wire February 3, 2020

Melanie Ivarsson, Ph.D. Joins Moderna as Chief Development Officer

Business Wire January 30, 2020

Moderna Announces Funding Award from CEPI to Accelerate Development of Messenger RNA (mRNA) Vaccine Against Novel Coronavirus

Business Wire January 23, 2020

Moderna Builds on Clinical Validation of Systemic Delivery with Two Additional Development Candidates in New Autoimmune Therapeutic Area

Business Wire January 12, 2020

Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

Business Wire January 9, 2020

Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

PR Newswire December 19, 2019